Biologics Expertise

Biologics are a class of medications made from living organisms or their products. They are different from traditional drugs, which are made from synthetic chemicals. Biologics are used to treat a wide range of diseases, including cancer, autoimmune diseases, and infectious diseases.

SR-Biologics-Hero-1

Bring Your Biologics Drug to Market Faster with Our Preclinical Expertise

Developing new biologics drugs is a complex and time-consuming process, but it also offers the potential to revolutionize the treatment of many diseases. The preclinical phase of drug development is particularly critical for biologics, as it requires a deep understanding of the drug’s molecular structure and function, as well as its potential impact on the body’s immune system.

That’s where Southern Research comes in. We have a team of experienced scientists and technicians with a deep understanding of biologics drug development and the preclinical testing process. We offer a comprehensive range of services to support you at every stage of preclinical development, including:

    • Target validation and identification
    • Assay development and screening
    • Lead optimization
    • Preclinical toxicology
    • Biodistribution and pharmacokinetics
    • Immunogenicity assessment

We also have state-of-the-art facilities and equipment to support all aspects of biologics drug development and testing.

Why choose our CRO for preclinical drug development and testing of biologics?

Expertise: We have a team of experienced scientists and technicians with a deep understanding of biologics drug development and the preclinical testing process.
Resources: We have state-of-the-art facilities and equipment to support all aspects of biologics drug development and testing.
Flexibility: We can tailor our services to meet your specific needs and budget.
Speed and efficiency: We are committed to helping our clients accelerate their preclinical work and bring their biologics drugs to market faster.

Contact us today to learn more about how we can help you accelerate your preclinical drug development and testing of biologics.

Viral Therapies

Viral therapies are a type of gene therapy that uses viruses to deliver therapeutic genes into cells. Viruses are naturally very good at getting into cells, so they make ideal vectors for gene therapy. Viral therapies are still under development, but they have the potential to revolutionize the treatment of a variety of diseases, including cancer, genetic disorders, and infectious diseases.

Learn more about our preclinical development services for Viral Therapies.

Antibodies

Antibody biologics are a type of biologic drug that uses the body’s own immune system to fight disease. They are designed to mimic the natural antibodies that the body produces to fight infection. Antibody biologics can be used to treat a wide variety of diseases, including cancer, autoimmune diseases, and infectious diseases.

Learn more about our preclinical development services for Antibodies.

Peptides

Peptide biologics are a type of biologic drug that is made up of peptides, which are short chains of amino acids. Peptides are naturally occurring molecules that play a variety of roles in the body, including cell communication, hormone regulation, and immune function. Peptide biologics are designed to mimic or enhance the natural functions of peptides in the body. They can be used to treat a wide range of diseases, including cancer, autoimmune diseases, and infectious diseases.

Learn more about our preclinical development services for Peptides.

Our Experts

Jennifer Pickens, Ph.D.

Director of Infectious Disease Research

Rebecca Boohaker, Ph.D.

Director of Oncology

Corinne E.
Augelli-Szafran, Ph.D.

Vice President of Scientific Platforms

Omar Moukha-Chafiq, Ph.D.

Director of Chemistry

Partner With Us

We have commercial, government, and industry partnership opportunities. Our work includes licensing patents, co-investing in furthering intellectual property, collaborating to create new intellectual property, and leveraging research to drive biotechnology product development.